Skip to content
IJCBR|ISSN: 2521-0394
Log in
IJ
IJCBR
Review ArticlesPeer-reviewedOpen Access · CC BY 4.0

MYASTHENIA GRAVIS, THYMOMA, AND THYMOMECTOMY: THE CLINICAL INTERPLAY.

Samuel Oyewole1, David Adeiza Otohinoyi2, Akinfisoye Toluwalase3, Ibukun Oshobu4, Ajibola Babatunde5, Temidayo Abe6, Esther Olunu7, Adegbenro Omotuyi John Fakoya8

  1. 1 All Saints University School of Medicine
  2. 2 All Saints Univesity School of Medicine
  3. 3 —
  4. 4 All Saints University School of Medicine
  5. 5 All Saints University School of Medicine
  6. 6 All Saints University School of Medicine
  7. 7 All Saints University School of Medicine
  8. 8 All Saints University School of Medicine (corresponding author)

DOI: 10.5455/ijcbr.2018.42.17 · Published 2018-04-15 · pp. 80-83

Download PDF

Abstract

Myasthenia gravis is an autoimmune disorder that places patients in debilitating condition. It currently affects 14 to 20 per 100,000 population. Its pathogenesis involves the destruction of acetylcholine receptor by antibodies produced by lymphocytes in the thymus gland. Symptoms could vary from impair extraocular muscles to generalized weakness. The antibodies have also been reported to affect other muscle structure within the body such as cardiomyocytes, leading to arrhythmia episodes which could be fatal. This review is a student project and involves the assessment of myasthenia gravis and the interplay between thymoma and thymomectomy.

References

  1. Murai H, Yamashita N, Watanabe M, Nomura Y, Motomura M, Yoshikawa H et al. Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. Journal of the Neurological Sciences. 2011;305(1-2):97-102. [Crossref] [Google Scholar]
  2. Huang K, Luo Y, Yang H, Yang X, Li J. Myasthenia gravis accompanied by Graves' disease, thyrotoxic hypokalemic periodic paralysis and thymic hyperplasia. Neurology India. 2016;64(4):783. [Crossref] [Google Scholar]
  3. Karni A, Asmail A, Drory V, Kolb H, Kesler A. Characterization of patients with ocular myasthenia gravis — A case series. eNeurologicalSci. 2016;4:30-33. [Crossref] [Google Scholar]
  4. Marx A, Porubsky S, Belharazem D, Saruhan-Direskeneli G, Schalke B, Ströbel P et al. Thymoma related myasthenia gravis in humans and potential animal models. Experimental Neurology. 2015;270:55-65. [Crossref] [Google Scholar]
  5. Bruno R. Different patterns of nicotinic acetylcholine receptor subunit transcription in human thymus. Journal of Neuroimmunology. 2004;149(1-2):147-159. [Crossref] [Google Scholar]
  6. Chu D, Johnson R, Pun S. Cathepsin B-sensitive polymers for compartment-specific degradation and nucleic acid release. Journal of Controlled Release. 2012;157(3):445-454. [Crossref] [Google Scholar]
  7. Casciola-Rosen L, Miagkov A, Nagaraju K, Askin F, Jacobson L, Rosen A et al. Granzyme B: Evidence for a role in the origin of myasthenia gravis. Journal of Neuroimmunology. 2008;201-202:33-40. [Crossref] [Google Scholar]
  8. Evoli A, Batocchi A, Minisci C, Di Schino C, Tonali P. Therapeutic options in ocular myasthenia gravis. Neuromuscular Disorders. 2001;11(2):208-216. [Crossref] [Google Scholar]
  9. Cho E, Min J, Lee S, Yoon C, Seok J, Cho H et al. Late-onset non-thymomatous myasthenia gravis: Comparison with early-onset and very late-onset myasthenia gravis. Neurology Asia. 2017;22(2):123-131. [Crossref] [Google Scholar]
  10. Meyer A, Levy Y. Chapter 33: Geoepidemiology of myasthenia gravis. Autoimmunity Reviews. 2010;9(5):A383-A386. [Crossref] [Google Scholar]
  11. Aarli J. Titin, Thymoma, and Myasthenia Gravis. Archives of Neurology. 2001;58(6):869. [Crossref] [Google Scholar]
  12. López-Cano M, Ponseti-Bosch J, Espin-Basany E, Sánchez-García J, Armengol-Carrasco M. Clinical and pathologic predictors of outcome in Thymoma-Associated myasthenia gravis. The Annals of Thoracic Surgery. 2003;76(5):1643-1649. [Crossref] [Google Scholar]
  13. Willcox N. Thymus and Thymoma in Myasthenia Gravis Patients. The Thymus Gland. :33-39. [Crossref] [Google Scholar]
  14. Conti-Fine B, Milani M, Kaminski H. Myasthenia gravis: past, present, and future. Journal of Clinical Investigation. 2006;116(11):2843-2854. [Crossref] [Google Scholar]
  15. Maggi L, Andreetta F, Antozzi C, Baggi F, Bernasconi P, Cavalcante P et al. Thymoma-associated myasthenia gravis: Outcome, clinical and pathological correlations in 197 patients on a 20-year experience. Journal of Neuroimmunology. 2008;201-202:237-244. [Crossref] [Google Scholar]
  16. Romi F. Thymoma in Myasthenia Gravis: From Diagnosis to Treatment. Autoimmune Diseases. 2011;2011:1-5. [Crossref] [Google Scholar]
  17. Lin J, Lu J, Zhao C, Qiao K, Zhu W, Yue D et al. Giant cell polymyositis associated with myasthenia gravis and thymoma. Journal of Clinical Neuroscience. 2014;21(12):2252-2254. [Crossref] [Google Scholar]
  18. Wolfe G, Kaminski H, Aban I, Minisman G, Kuo H, Marx A et al. Randomized Trial of Thymectomy in Myasthenia Gravis. New England Journal of Medicine. 2016;375(6):511-522. [Crossref] [Google Scholar]
  19. Aydin Y, Ulas A, Mutlu V, Colak A, Eroglu A. Thymectomy in Myasthenia Gravis. The Eurasian Journal of Medicine. 2017;49(1):48-52. [Crossref] [Google Scholar]